Monitoring the bioavailability of FEIBA with a thrombin generation assay
- 1 November 2003
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (11), 2374-2380
- https://doi.org/10.1046/j.1538-7836.2003.00450.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluationBritish Journal of Haematology, 2003
- The Thrombogram in Rare Inherited Coagulation Disorders: Its Relation to Clinical BleedingThrombosis and Haemostasis, 2002
- The Use of Agents that By–Pass Factor VIII Inhibitors in Patients with HaemophiliaVox Sanguinis, 1999
- Factor Xa and prothrombin: mechanism of action of FEIBA.Published by Wiley ,1999
- Phospholipid-bound Tissue Factor Modulates both Thrombin Generation and APC-mediated Factor Va InactivationThrombosis and Haemostasis, 1999
- Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX InhibitorsThrombosis and Haemostasis, 1997
- Inhibition of thrombin generation by heparin and LMW heparinsBlood Coagulation & Fibrinolysis, 1996
- The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.JCI Insight, 1993
- Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion, 1990
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIINew England Journal of Medicine, 1988